Cyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
CYCCCyclacel(CYCC) GlobeNewswire News Room·2024-06-04 20:00
  • Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced a presentation by independent investigators of preclinical data demonstrating therapeutic potential of fadraciclib, the Company's cyclindependen ...